A Breast Cancer Vaccine (SV-BR-1-GM) in Combination With Pembrolizumab for the Treatment of Persistent, Recurrent, or Metastatic Breast Cancer
Conditions: Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Breast Carcinoma; Prognostic Stage IV Breast Cancer AJCC v8; Recurrent Breast Carcinoma; Refractory Breast Carcinoma Interventions: Drug: Cyclophosphamide; Biological: Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM; Biological: Pembrolizumab; Biological: Recombinant Interferon Alpha 2b-like Protein; Other: Questionnaire Administration; Other: Quality of Life Assessment Sponsor: Thomas Jefferson University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Cancer Vaccines | Carcinoma | Research | Vaccines